1. Home
  2. THRD vs HCAT Comparison

THRD vs HCAT Comparison

Compare THRD & HCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THRD
  • HCAT
  • Stock Information
  • Founded
  • THRD 2019
  • HCAT 2008
  • Country
  • THRD United States
  • HCAT United States
  • Employees
  • THRD N/A
  • HCAT N/A
  • Industry
  • THRD Biotechnology: Pharmaceutical Preparations
  • HCAT Computer Software: Programming Data Processing
  • Sector
  • THRD Health Care
  • HCAT Technology
  • Exchange
  • THRD Nasdaq
  • HCAT Nasdaq
  • Market Cap
  • THRD 512.9M
  • HCAT 464.4M
  • IPO Year
  • THRD 2022
  • HCAT 2019
  • Fundamental
  • Price
  • THRD $13.93
  • HCAT $8.86
  • Analyst Decision
  • THRD Strong Buy
  • HCAT Buy
  • Analyst Count
  • THRD 3
  • HCAT 10
  • Target Price
  • THRD $20.33
  • HCAT $11.56
  • AVG Volume (30 Days)
  • THRD 184.1K
  • HCAT 486.0K
  • Earning Date
  • THRD 11-07-2024
  • HCAT 11-06-2024
  • Dividend Yield
  • THRD N/A
  • HCAT N/A
  • EPS Growth
  • THRD N/A
  • HCAT N/A
  • EPS
  • THRD N/A
  • HCAT N/A
  • Revenue
  • THRD N/A
  • HCAT $302,062,000.00
  • Revenue This Year
  • THRD N/A
  • HCAT $5.98
  • Revenue Next Year
  • THRD N/A
  • HCAT $11.42
  • P/E Ratio
  • THRD N/A
  • HCAT N/A
  • Revenue Growth
  • THRD N/A
  • HCAT 4.15
  • 52 Week Low
  • THRD $5.82
  • HCAT $5.42
  • 52 Week High
  • THRD $16.94
  • HCAT $11.41
  • Technical
  • Relative Strength Index (RSI)
  • THRD 54.76
  • HCAT 64.84
  • Support Level
  • THRD $11.69
  • HCAT $7.41
  • Resistance Level
  • THRD $14.64
  • HCAT $8.05
  • Average True Range (ATR)
  • THRD 0.99
  • HCAT 0.48
  • MACD
  • THRD -0.04
  • HCAT 0.03
  • Stochastic Oscillator
  • THRD 67.67
  • HCAT 88.96

About THRD Third Harmonic Bio Inc.

Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

About HCAT Health Catalyst Inc

Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.

Share on Social Networks: